Cue Biopharma, Inc.
CUE
$30.44
$1.364.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 195.75% | -25.51% | -0.11% | 13.83% | 69.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 195.75% | -25.51% | -0.11% | 13.83% | 69.16% |
| Cost of Revenue | 5.78% | -36.04% | -26.32% | -24.45% | -20.72% |
| Gross Profit | 66.50% | 39.25% | 32.91% | 32.04% | 34.06% |
| SG&A Expenses | 6.74% | 32.97% | 14.45% | 8.07% | 14.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.11% | -18.06% | -15.38% | -15.58% | -11.49% |
| Operating Income | 36.24% | 16.50% | 18.01% | 19.61% | 20.00% |
| Income Before Tax | 35.83% | 15.53% | 17.17% | 18.78% | 19.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.60% | 15.53% | 17.17% | 18.78% | 19.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.60% | 15.53% | 17.17% | 18.78% | 19.83% |
| EBIT | 36.24% | 16.50% | 18.01% | 19.61% | 20.00% |
| EBITDA | 37.95% | 16.58% | 18.09% | 19.64% | 19.91% |
| EPS Basic | 58.22% | 49.70% | 43.46% | 37.64% | 32.49% |
| Normalized Basic EPS | 58.98% | 49.69% | 43.08% | 37.27% | 32.13% |
| EPS Diluted | 58.17% | 49.70% | 43.46% | 37.64% | 32.49% |
| Normalized Diluted EPS | 58.92% | 49.69% | 43.08% | 37.27% | 32.13% |
| Average Basic Shares Outstanding | 68.17% | 74.09% | 52.79% | 33.05% | 23.01% |
| Average Diluted Shares Outstanding | 69.29% | 74.09% | 52.79% | 33.05% | 23.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |